Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	4.55B 3.92B 3.69B 3.36B 6.28B 433B 6.31B 43.69B 16.89B 221B 17.08B 16.71B 699B	P/E 2024	-51.1x	P/E 2025	-162x
Enterprise Value	4.7B 4.04B 3.81B 3.47B 6.49B 447B 6.52B 45.12B 17.44B 228B 17.64B 17.26B 722B	EV / Sales 2024	5.69x	EV / Sales 2025	7.18x
Free-Float	99.31%	Yield 2024 *	-	Yield 2025	-

May. 05	BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says	MT
Apr. 28	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P Global BMI Index	CI
Apr. 28	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P TMI Index	CI
Apr. 28	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P Biotechnology Select Industry Index	CI
Apr. 27	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 3000E Index	CI
Apr. 27	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 3000E Growth Benchmark	CI
Apr. 27	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 3000 Growth Benchmark	CI
Apr. 27	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2500 Growth Benchmark	CI
Apr. 27	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2000 Growth Benchmark	CI
Apr. 27	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2500 Growth-Dynamic Index	CI
Apr. 27	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2000 Growth-Dynamic Index	CI
Apr. 27	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2500 Dynamic Index	CI
Apr. 27	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 3000E Growth Index	CI

May. 05	BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says	MT
Jan. 22	Jefferies Downgrades Amicus Therapeutics to Hold From Buy, Adjusts Price Target to $14.50 From $16	MT
Dec. 29	Leerink Downgrades Amicus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $14.50 From $17	MT
Dec. 22	TD Cowen Downgrades Amicus Therapeutics to Hold From Buy, Adjusts PT to $14.50 From $20	MT
Dec. 19	Top Midday Gainers	MT

Mar. 09	US Senate Probes FDA Bureaucracy vs. Innovation	AQ
Feb. 23	Amicus Therapeutics: Q4 Earnings Snapshot	AQ
Feb. 20	Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates	AQ
Feb. 03	Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026	AQ
Jan. 09	Amicus Therapeutics : Legend (1)	PU

Feb. 20	BB Biotech bestätigt Gewinn 2025
Dec. 19	Wall Street optimistisch het weekend in
Dec. 19	MÄRKTE USA/Zinssenkungshoffnung stützen Börse - Oracle fest
Dec. 19	MÄRKTE USA/Börsen von Zinssenkungshoffnung gestützt - Oracle fest
Dec. 19	MÄRKTE USA/Positive Stimmung hält - Oracle mit TikTok-Deal fest

Amicus Therapeutics Stock Nasdaq

Stocks

Biotechnology & Medical Research

Valuation : Amicus Therapeutics

Latest news : Amicus Therapeutics

Last Transcript : Amicus Therapeutics

Analysts' recommendations : Amicus Therapeutics

Press Releases : Amicus Therapeutics

News in other languages : Amicus Therapeutics

Quotes and Performance

Managers and Directors : Amicus Therapeutics

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMICUS THERAPEUTICS	+1.57%	+1.65%	-	-	4.55B
LONZA GROUP AG	-3.24%	-6.89%	-5.65%	+11.20%	48.01B
REVOLUTION MEDICINES, INC.	+0.17%	-0.74%	+407.28%	+531.82%	44.44B
IQVIA HOLDINGS INC.	-0.86%	-2.60%	+35.51%	+19.34%	42.67B
BEONE MEDICINES AG	-0.14%	-2.98%	-0.04%	+67.75%	39.96B
CELLTRION, INC.	0.00%	-2.61%	+13.09%	+42.33%	32.75B
ASCENDIS PHARMA A/S	-3.44%	-2.43%	-	-	17.74B
MEDPACE HOLDINGS, INC.	-0.78%	-1.13%	+20.74%	+109.88%	16.49B
EUROFINS SCIENTIFIC SE	-0.37%	-0.87%	+10.98%	+30.93%	14.38B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.86%	-4.60%	+76.86%	+39.41%	13.4B
Average	-0.75%	-0.53%	+69.85%	+106.58%	29.98B
Weighted average by Cap.	-0.91%	-1.10%	+84.49%	+126.44%

	2024	2025
Net sales	528M 455M 428M 390M 730M 50.27B 733M 5.07B 1.96B 25.61B 1.98B 1.94B 81.13B	634M 546M 514M 468M 876M 60.35B 880M 6.09B 2.35B 30.74B 2.38B 2.33B 97.4B
Net income	-56.11M -48.28M -45.46M -41.42M -77.5M -5.34B -77.81M -539M -208M -2.72B -211M -206M -8.62B	-27.11M -23.33M -21.97M -20.01M -37.45M -2.58B -37.6M -260M -101M -1.31B -102M -99.59M -4.16B
Net Debt	194M 167M 157M 143M 268M 18.43B 269M 1.86B 719M 9.39B 727M 712M 29.75B	149M 128M 121M 110M 206M 14.16B 206M 1.43B 552M 7.21B 559M 547M 22.86B